p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells
- 1 September 2015
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 464 (4) , 1267-1274
Abstract
No abstract availableKeywords
Funding Information
- American Cancer Society (RSG-08-138-01-CNE)
- NIH (U54 AA019765, 5U54CA156735)
This publication has 22 references indexed in Scilit:
- Targeted Therapy for Breast Cancer PreventionFrontiers in Oncology, 2013
- p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated TranscriptionPLOS ONE, 2012
- The role of p53 in cell metabolismActa Pharmacologica Sinica, 2010
- Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivoCell Cycle, 2010
- p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal CompartmentCold Spring Harbor Perspectives in Biology, 2009
- Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell GrowthCancer Research, 2007
- AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancerThe Journal of Physiology, 2006
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Pharmacological Rescue of Mutant p53 Conformation and FunctionScience, 1999
- The p53 tumour suppressor geneNature, 1991